FDMT (4D Molecular Therapeutics, Inc. Common Stock) Stock Analysis - Politician Trades
4D Molecular Therapeutics, Inc. Common Stock (FDMT) is a publicly traded Healthcare sector company. As of May 21, 2026, FDMT trades at $8.49 with a market cap of $437.29M and a P/E ratio of -3.28. FDMT moved +0.89% today. Year to date, FDMT is +16.03%; over the trailing twelve months it is +120.00%. Its 52-week range spans $2.24 to $12.34. Analyst consensus is strong buy with an average price target of $29.00. Rallies surfaces FDMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded FDMT stock?
Rallies tracks politician and congressional stock disclosures for FDMT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Rallies tracks politician and congressional stock disclosures for FDMT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in FDMT?
Yes. Rallies tracks politician and congressional stock disclosures for FDMT, including reported purchases, sales, dates, owners, and trade amounts when available.
Is FDMT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for FDMT. It does not provide personalized investment advice.